Aegis reiterated their buy rating on shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) in a research report released on Monday.

Several other equities research analysts have also weighed in on the company. Cantor Fitzgerald initiated coverage on Corbus Pharmaceuticals Holdings in a research report on Tuesday, October 4th. They set a buy rating and a $17.00 target price on the stock. Noble Financial reissued a buy rating and set a $19.00 target price on shares of Corbus Pharmaceuticals Holdings in a research report on Friday, November 11th.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 7.80 on Monday. Corbus Pharmaceuticals Holdings has a 12-month low of $1.01 and a 12-month high of $10.78. The company’s market capitalization is $346.62 billion. The company has a 50 day moving average price of $7.22 and a 200 day moving average price of $4.47.

In other news, CFO Sean F. Moran purchased 17,900 shares of the company’s stock in a transaction that occurred on Friday, August 26th. The shares were purchased at an average price of $3.92 per share, for a total transaction of $70,168.00. Following the purchase, the chief financial officer now directly owns 299,310 shares of the company’s stock, valued at approximately $1,173,295.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sean F. Moran purchased 30,800 shares of the company’s stock in a transaction that occurred on Thursday, September 8th. The shares were purchased at an average price of $5.12 per share, for a total transaction of $157,696.00. Following the purchase, the chief financial officer now directly owns 330,110 shares in the company, valued at $1,690,163.20. The disclosure for this purchase can be found here. Corporate insiders own 11.60% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Knoll Capital Management LP purchased a new position in Corbus Pharmaceuticals Holdings during the third quarter worth about $16,717,000. Fosun International Ltd purchased a new position in Corbus Pharmaceuticals Holdings during the third quarter worth about $4,753,000. Morgan Stanley increased its position in Corbus Pharmaceuticals Holdings by 12.4% in the third quarter. Morgan Stanley now owns 29,909 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,300 shares in the last quarter. Northern Trust Corp increased its position in Corbus Pharmaceuticals Holdings by 41.0% in the third quarter. Northern Trust Corp now owns 45,436 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 13,222 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its position in Corbus Pharmaceuticals Holdings by 14.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 216,139 shares of the biopharmaceutical company’s stock worth $1,468,000 after buying an additional 27,000 shares in the last quarter. Hedge funds and other institutional investors own 25.39% of the company’s stock.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.